After enduring many challenges with its vaccine, the drugmaker AstraZeneca has shown that its long-acting antibody drug reduced the risk of symptomatic coronavirus infection by 77%. These results are obtained after a study at an advanced stage, prompting the company to seek emergency approval. An executive at the pharmaceutical company said the prospect of offering a new treatment to prevent Covid-19 could position the UK drug maker as a supplier of both vaccines and drugs that protect against the disease.
According to company officials, the antibody drug AZD7442 prevents Covid-19. There have been no cases of severe Covid-19 or virus-related deaths after administration of the AZD7442. The announcement of these results came after another top executive, Ruud Dobber, said last month that different options were being explored for immunization operations, which stem from a collaboration with Oxford University. « When we talked about the vaccine decisions, we obviously said that we also wanted to see what the results of 7442 were. », Confided an official to Reuters.
The first delivered two molecules against the Covid
« No other company has delivered two molecules against SARS-CoV2. It certainly helps us position ourselves in terms of Covid “, he added. While several Covid-19 vaccines have been invented, tested and deployed at unusually fast speeds, the development of reliable antibody treatments and other therapies has been slower, with more mixed results. But recently, antibody treatments have raised hopes as valuable tools in tackling severe cases and reducing deaths.
–
